170 related articles for article (PubMed ID: 11677139)
1. The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.
Levin JI; Chen JM; Du MT; Nelson FC; Wehr T; DiJoseph JF; Killar LM; Skala S; Sung A; Sharr MA; Roth CE; Jin G; Cowling R; Di L; Sherman M; Xu ZB; March CJ; Mohler KM; Black RA; Skotnicki JS
Bioorg Med Chem Lett; 2001 Nov; 11(22):2975-8. PubMed ID: 11677139
[TBL] [Abstract][Full Text] [Related]
2. The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.
Levin JI; Chen J; Du M; Hogan M; Kincaid S; Nelson FC; Venkatesan AM; Wehr T; Zask A; DiJoseph J; Killar LM; Skala S; Sung A; Sharr M; Roth C; Jin G; Cowling R; Mohler KM; Black RA; March CJ; Skotnicki JS
Bioorg Med Chem Lett; 2001 Aug; 11(16):2189-92. PubMed ID: 11514167
[TBL] [Abstract][Full Text] [Related]
3. The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position.
Levin JI; Du MT; DiJoseph JF; Killar LM; Sung A; Walter T; Sharr MA; Roth CE; Moy FJ; Powers R; Jin G; Cowling R; Skotnicki JS
Bioorg Med Chem Lett; 2001 Jan; 11(2):235-8. PubMed ID: 11206467
[TBL] [Abstract][Full Text] [Related]
4. Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.
Levin JI; Chen JM; Cheung K; Cole D; Crago C; Santos ED; Du X; Khafizova G; MacEwan G; Niu C; Salaski EJ; Zask A; Cummons T; Sung A; Xu J; Zhang Y; Xu W; Ayral-Kaloustian S; Jin G; Cowling R; Barone D; Mohler KM; Black RA; Skotnicki JS
Bioorg Med Chem Lett; 2003 Aug; 13(16):2799-803. PubMed ID: 12873518
[TBL] [Abstract][Full Text] [Related]
5. Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 1: Structure-based design of novel acetylenic P1' groups.
Chen JM; Jin G; Sung A; Levin JI
Bioorg Med Chem Lett; 2002 Apr; 12(8):1195-8. PubMed ID: 11934587
[TBL] [Abstract][Full Text] [Related]
6. Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group.
Levin JI; Chen JM; Du MT; Nelson FC; Killar LM; Skala S; Sung A; Jin G; Cowling R; Barone D; March CJ; Mohler KM; Black RA; Skotnicki JS
Bioorg Med Chem Lett; 2002 Apr; 12(8):1199-202. PubMed ID: 11934588
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological activity of piperazine-based dual MMP-13 and TNF-alpha converting enzyme inhibitors.
Letavic MA; Barberia JT; Carty TJ; Hardink JR; Liras J; Lopresti-Morrow LL; Mitchell PG; Noe MC; Reeves LM; Snow SL; Stam EJ; Sweeney FJ; Vaughn ML; Yu CH
Bioorg Med Chem Lett; 2003 Oct; 13(19):3243-6. PubMed ID: 12951101
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.
Zask A; Gu Y; Albright JD; Du X; Hogan M; Levin JI; Chen JM; Killar LM; Sung A; DiJoseph JF; Sharr MA; Roth CE; Skala S; Jin G; Cowling R; Mohler KM; Barone D; Black R; March C; Skotnicki JS
Bioorg Med Chem Lett; 2003 Apr; 13(8):1487-90. PubMed ID: 12668018
[TBL] [Abstract][Full Text] [Related]
9. Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases.
Levin JI; Gu Y; Nelson FC; Zask A; DiJoseph JF; Sharr MA; Sung A; Jin G; Cowling R; Chanda P; Cosmi S; Hsiao CL; Edris W; Wilhelm J; Killar LM; Skotnicki JS
Bioorg Med Chem Lett; 2001 Jan; 11(2):239-42. PubMed ID: 11206468
[TBL] [Abstract][Full Text] [Related]
10. alpha-Alkyl-alpha-amino-beta-sulphone hydroxamates as potent MMP inhibitors that spare MMP-1.
Becker DP; DeCrescenzo G; Freskos J; Getman DP; Hockerman SL; Li M; Mehta P; Munie GE; Swearingen C
Bioorg Med Chem Lett; 2001 Oct; 11(20):2723-5. PubMed ID: 11591510
[TBL] [Abstract][Full Text] [Related]
11. alpha-Amino-beta-sulphone hydroxamates as potent MMP-13 inhibitors that spare MMP-1.
Becker DP; Barta TE; Bedell L; DeCrescenzo G; Freskos J; Getman DP; Hockerman SL; Li M; Mehta P; Mischke B; Munie GE; Swearingen C; Villamil CI
Bioorg Med Chem Lett; 2001 Oct; 11(20):2719-22. PubMed ID: 11591509
[TBL] [Abstract][Full Text] [Related]
12. The development of new carboxylic acid-based MMP inhibitors derived from a cyclohexylglycine scaffold.
Tullis JS; Laufersweiler MJ; VanRens JC; Natchus MG; Bookland RG; Almstead NG; Pikul S; De B; Hsieh LC; Janusz MJ; Branch TM; Peng SX; Jin YY; Hudlicky T; Oppong K
Bioorg Med Chem Lett; 2001 Aug; 11(15):1975-9. PubMed ID: 11454461
[TBL] [Abstract][Full Text] [Related]
13. Sulfonate ester hydroxamic acids as potent and selective inhibitors of TACE enzyme.
Levin JI; Du MT
Drug Des Discov; 2003; 18(4):123-6. PubMed ID: 15553924
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and activity of selective MMP inhibitors with an aryl backbone.
Barta TE; Becker DP; Bedell LJ; De Crescenzo GA; McDonald JJ; Munie GE; Rao S; Shieh HS; Stegeman R; Stevens AM; Villamil CI
Bioorg Med Chem Lett; 2000 Dec; 10(24):2815-7. PubMed ID: 11133099
[TBL] [Abstract][Full Text] [Related]
15. N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.
Nuti E; Casalini F; Avramova SI; Santamaria S; Cercignani G; Marinelli L; La Pietra V; Novellino E; Orlandini E; Nencetti S; Tuccinardi T; Martinelli A; Lim NH; Visse R; Nagase H; Rossello A
J Med Chem; 2009 Aug; 52(15):4757-73. PubMed ID: 19606871
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.
Aranapakam V; Grosu GT; Davis JM; Hu B; Ellingboe J; Baker JL; Skotnicki JS; Zask A; DiJoseph JF; Sung A; Sharr MA; Killar LM; Walter T; Jin G; Cowling R
J Med Chem; 2003 Jun; 46(12):2361-75. PubMed ID: 12773041
[TBL] [Abstract][Full Text] [Related]
17. Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket.
Huang A; Joseph-McCarthy D; Lovering F; Sun L; Wang W; Xu W; Zhu Y; Cui J; Zhang Y; Levin JI
Bioorg Med Chem; 2007 Sep; 15(18):6170-81. PubMed ID: 17606376
[TBL] [Abstract][Full Text] [Related]
18. Design strategies for the identification of MMP-13 and Tace inhibitors.
Skotnicki JS; DiGrandi MJ; Levin JI
Curr Opin Drug Discov Devel; 2003 Sep; 6(5):742-59. PubMed ID: 14579524
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.
Aranapakam V; Davis JM; Grosu GT; Baker J; Ellingboe J; Zask A; Levin JI; Sandanayaka VP; Du M; Skotnicki JS; DiJoseph JF; Sung A; Sharr MA; Killar LM; Walter T; Jin G; Cowling R; Tillett J; Zhao W; McDevitt J; Xu ZB
J Med Chem; 2003 Jun; 46(12):2376-96. PubMed ID: 12773042
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and identification of conformationally constrained selective MMP inhibitors.
Freskos JN; McDonald JJ; Mischke BV; Mullins PB; Shieh HS; Stegeman RA; Stevens AM
Bioorg Med Chem Lett; 1999 Jul; 9(13):1757-60. PubMed ID: 10406637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
